BF Biosciences gains DRAP's approval for brownfield expansion

September 09, 2024 (MLN): BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited (PSX: FEROZ), has secured approval from the Drug Regulatory Authority of Pakistan (DRAP) for its brownfield expansion (Line II).

This expansion includes a pre-filled syringes line, a liquid and lyophilized line, and a product development section.

The commercial production from the pre-filled syringes line has commenced, whereas the liquid & lyophilized line is under internal validation and will start commercial production in the second quarter of FY 2024­-25.

Additionally, BF Biosciences Limited has launched Sematide (Semaglutide) in a pre-filled syringe.

Sematide is the first Glucagon-Like Peptide 1 (GLP1) receptor agonist approved for local manufacture in Pakistan, offering a convenient solution for diabetes management.

The pre-filled syringe eliminates dosing errors and is easy to use by the patients.

Sematide is being manufactured at the new state-of-the-art European prefilled syringes line of BF Biosciences Limited.

Copyright Mettis Link News